Home Blog

The Europe cannabis testing market is expected to reach US$ 770.30 million by 2027 from US$ 431.58 million in 2019

0

New York, Jan. 15, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Europe Cannabis Testing Market Forecast to 2027 – COVID-19 Impact and Regional Analysis by Product ; Service ; End User, and Country” – https://www.reportlinker.com/p06004156/?utm_source=GNW
However, the cannabis used as a street drug and trouble with CBD oil are the factors negatively impacting the growth of the market in the coming years.
With the legalization of Cannabis in Europe, producers are looking for a quick and accurate means of determining their products’ quality and potency.The growing use of Cannabis results in increasing demand for Cannabis testing, which, in turn promotes the research activities in the region.

The European Parliament is calling for an EU-wide policy for medical Cannabis and properly funded scientific research. To achieve this, in February 2019, members of the European Parliament (MEPs) adopted a resolution on the use of Cannabis for medicinal purposes.
Various European countries have legalized the medical use of Cannabis or cannabinoids and are considering their legislation changes for legalization of Cannabis. The main purpose of the resolution is to draw a clear distinction between medical Cannabis and other Cannabis uses.
However, no EU country authorizes the smoking or home-growing of Cannabis for medical purposes.At the same time, the World Health Organization (WHO) has officially recommended that the Cannabis compound cannabidiol (CBD) should not be classified as a controlled substance.

However, at present, there are no EU-wide rules for either the medical or recreational use of Cannabis in the region.
The Cannabis or cannabinoids have therapeutic effects in stimulating appetite and alleviating mental disorders or epilepsy, asthma, cancer, and Alzheimer’s. The MEPs’ primary purpose is to address research gaps on medical Cannabis in the region and call member states to seize the potential of Cannabis-based medicines.
Thus, the need for more research in the therapeutic area and stimulating innovation regarding medicinal Cannabis projects is expected to witness rapid growth of the market in the region.
Based on product, the Europe cannabis testing market is segmented into chromatography instruments, spectroscopy, consumables, and software.The market players are offering diverse portfolio of cannabis testing products to the healthcare industry for innovations in the technologies.

In 2019, the chromatography instruments segment held the largest share of the market and is expected to witness the highest CAGR in the market owing to increasing analytical services and medicinal cannabis testing services.
Based on service, the European cannabis market is segmented into potency testing, microbial analysis, residual solvent screening, heavy metal testing, pesticide screening, terpene profiling, and genetic testing. In 2019, potency testing segment held the largest share of the market, and is expected to grow at the fastest rate during the coming years.
Based on end user, the Europe cannabis testing market is segmented into testing laboratories, drug manufacturers, and research institutes.In 2019, the testing laboratories segment held the largest share of the market, and is expected to grow at the fastest rate during the coming years.

The growth of the segment is attributed to the increasing number of diagnostic testing performed in the reference labs for numerous diseases.
National Research Foundation, National Center for Biotechnology Information, and European Union and National Science Foundation are among the major primary and secondary sources for the Europe Cannabis testing market.
Read the full report: https://www.reportlinker.com/p06004156/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Plant&Co. Retains Digitonic Ltd. for Marketing Services

0

Toronto, Ontario–(Newsfile Corp. – January 15, 2021) – Plant&Co. Brands Ltd. (CSE: VEGN) (FSE: VGP) (OTC Pink: VGANF) (“Plant&Co.” or the “Company“), is pleased to announce that it has retained Digitonic Ltd., an arm’s-length party to the Company and a leading investor relations and mobile marketing firm based in Glasgow, Scotland, to provide marketing services focused on the North American markets.

Under the agreement, Digitonic is to provide content creation, distribution, and advertising services in North America. The Company agrees to pay the service provider up to US$500,000 over a 4-month period.

About Plant&Co. Brands Ltd.

Plant&Co. Brands (CSE: VEGN) (FSE: VGP) (OTC Pink: VGANF) is modern health and wellness company curating delicious plant-based foods.

For additional information, please contact: Shawn Moniz, CEO, ir@plantandco.com or visit www.PlantandCo.com.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for Plant&Co. Brands described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Companys Managements Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72134

MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors

0

TORONTO, Jan. 15, 2021 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced the appointment of Warren Everitt to its Board of Directors (the “Board”), effective immediately.  

Mr. Everitt joined MediPharm Labs in 2017 to establish the Company’s presence in the Australian market. As the founding CEO of Australia Pacific, he oversaw all aspects of the build out, start-up and commercialization of the GMP-certified extraction operation in Wonthaggi, Australia including licensing, factory design, finance, sales and marketing. Under his ongoing leadership, MediPharm Labs Australia has developed an impressive customer portfolio in the Asia Pacific and European medical and wellness cannabis markets.

“In reviewing the stewardship needs of a business that is rapidly expanding in the most promising cannabis markets worldwide, the Board concluded that Warren’s unique expertise, diverse perspectives and two decades of proven international experience would be highly accretive to MediPharm Labs’ corporate governance,” said Pat McCutcheon, Chairman, MediPharm Labs. “From start up to commercialization and now to operationalization of MediPharm Labs Australia as a dominant producer, Warren has achieved what few executives in our nascent industry have and has done so cost effectively and with a keen eye to talent development. For these reasons, we are delighted to welcome Warren to the Board.”

Before joining MediPharm Labs first as Managing Director, Australia, and subsequently being appointed CEO Australia Pacific, Mr. Everitt served in progressively more responsible leadership roles at MarketOne International, a global consulting firm specializing in marketing and lead generation. Over eight years, he founded MarketOne’s Asia Pacific operations in Melbourne, Singapore, Bangalore and Tokyo that serve some of the world’s leading brands. Earlier in his 20-year career he served as a consultant in the UK, Europe, Singapore and Canada and founded a leadership and performance coaching consultancy. He is a graduate of Swinburne University of Technology (Bachelor of Computer Science) and Chisholm Institute in Melbourne. An Australian citizen, he currently resides in Melbourne.

“As pharmaceutical and manufacturing experts with two fully GMP certified platforms and a portfolio of enabling licences, MediPharm Labs is positioned for a new wave of growth as we open the door to sophisticated new pharma accounts and new medical and wellness-focused cannabis companies in emerging international jurisdictions,” said Mr. Everitt. “Through this Board appointment, I look forward to serving with experienced, invested Directors who are setting the tone for disciplined execution that benefits all stakeholders.”

With Mr. Everitt’s appointment, MediPharm Labs’ Board of Directors will consist of eight members, five of whom are independent.   The independent members include recognized experts in the pharmaceutical, pharmacy, consumer packaged goods, clinical research, finance and capital markets industries.

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and has fully commercialized its wholly-owned Australian extraction facility. MediPharm Labs Australia was established in 2017.

For further information, please contact:
Laura Lepore, VP, Investor Relations
Telephone: 705-719-7425 ext 1525
Email: investors@medipharmlabs.com  
Website: www.medipharmlabs.com 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: rapid expansion in the most promising cannabis markets worldwide; a new wave of growth; sophisticated new pharma accounts; new medical and wellness-focused cannabis companies in emerging international jurisdiction; and disciplined execution that benefits all stakeholders. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

Innocan Pharma Successfully Completes Large Scale Production of Exosomes

0

Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – January 14, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan“), is pleased to announce the successful completion of a large-scale production of exosomes. Innocan’s CBD Loaded Exosome (CLX) Therapy project led by Prof. Offen demonstrates the capability of having reliable large-scale production of exosomes and is an important milestone in the CLX Therapy development process. Innocan managed to perform the production of trillions of exosomes in a short period of time in a 3-dimensional bioreactor, and that may lead to economic large scale exosome production for the CLX. This achievement is expected to pave the way for larger tests and studies.

“Innocan is now one of a few public companies in the exosome’s science field. Although we are still in the development stage of the CLX platform, large scale exosome production capabilities are a significant proof of advantage and capability for Innocan, as part of the path to commercialization,” said Iris Bincovich, founder and CEO of Innocan.

Innocan Pharma together with Tel Aviv University, Prof. Offen and his team, are developing a new revolutionary cell therapy – based technology, loaded with CBD (Cannabidiol), designed to target coronavirus infected lung cells and central nervous system diseases. The CLX Therapy holds the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product is planned to act as a “guided missile” to the infected lungs, combining the cell healing properties of exosomes and the anti-inflammatory properties of CBD.

Prof. Offen of Tel Aviv University stated: “To demonstrate the ability of a semi-commercial exosome production from a human cell source which can serve as the source of the CLX platform is a key milestone at the development stages. Now, when we know we can produce exosomes in large quantities we can concentrate on the CBD loading technologies and examine different potential indications for the use of the CLX Therapy”.

Innocan also announces that it has issued 1,700,000 common shares to a third party consultant under a service agreement at a price of $0.36 per share.

About Innocan

The Company, through Innocan Israel, its wholly owned subsidiary, is a pharmaceutical tech company that focuses on the development of several drug delivery platforms using CBD. Innocan Israel and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the COVID-19 coronavirus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan Israel signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop a CBD drug delivery platform based on a unique-controlled release liposome to be administrated by injection. Innocan Israel plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University, to test the liposome platform on several potential indications. Innocan Israel is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72078

RETRANSMISSION: Sweet Earth Receives Export Certification from United States Government

0

Vancouver, British Columbia–(Newsfile Corp. – January 14, 2021) – Sweet Earth Holdings Corp. (CSE: SE) (FSE: 1KZ1) (OTCQB: SEHCF) ("Sweet Earth" the "Company") is pleased to announce that it has received a Certificate of Free Sale from the Los Angles Chamber of Commerce, allowing the Company to export its Organic Hemp Lip Balm, Organic Hemp Hydration Cream, and Organic Hemp Salve internationally.

A Certificate of Free Sale is a document required in certain countries or for certain commodities, certifying that the specified imported goods are normally and freely sold in the exporting country’s open markets and are approved. The certification is the first step in exporting its products to Central America, South America, and Europe. The Company has already spent one year in garnering importation certification for Central America and South America and is in the application process to send retail products to Europe and Asia.

About Sweet Earth

Corporate Website: https://www.sweetearthcbdcorp.com/

Sweet Earth is a vertically integrated "farm to shelf" hemp grower with a farm in Applegate, Oregon, that maintains a full line of hemp and CBD products for the US and global market. Its products combine CBD with herbal and organic ingredients, all of which are selected for their beneficial properties to soothe, rejuvenate, and reduce inflammation. In addition to high-end finished products, Sweet Earth prides itself on sustainability by minimizing the use of plastics in both production and packaging. Sweet Earth’s in-house genetics team has been working on its own proprietary hemp strain.

Sweet Earth maintains a portfolio of products that includes facial and body care, men’s, spa, hemp, and muscle products that are sold on its website, https://sweetearthskincare.com.

Sweet Earth also operates a proprietary online shopping portal for discerning pet owners offering pet treats comprised of high-quality ingredients, which are further enriched with CBD and Vitamin E. The treats are sold on its website: https://www.sweetearthpets.com.

ON BEHALF OF THE BOARD

"Peter Espig"

For additional information contact:

Peter Espig / CEO and Director
Telephone: (778) 385-1213
Email: info@sweetearthcbd.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72033

PAOG Publishes 2021 Cannabis Biopharmaceutical Strategic Outlook

0

Sandusky, Ohio–(Newsfile Corp. – January 14, 2021) – PAO Group, Inc. (OTC Pink: PAOG) today published a management outlook for 2021 on the company’s strategy to develop and monetize the cannabis assets acquired last year. The strategic outlook is included in its entirety below:

PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook

PAOG is a longtime participant in the cannabis sector working on initiatives to introduce cannabis treatments as alternatives to traditional pharmaceuticals, particularly where existing pharmaceutical treatments have potentially severe secondary ramifications as is the case with opioid based treatments.

Last year, the company shifted its primary focus to the development biopharmaceutical treatments derived from cannabis.

On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”

PAOG also acquired a of hemp cultivation business from Puration, Inc. (OTC Pink: PURA). This operation comes with existing sales activity and PAOG expects to report its first revenue from the acquisition in conjunction with the inclusion of Q4 2020 results into the overall 2020 financial report.

Since the two acquisitions, PAOG has been working diligently to develop and execute upon a strategy to monetize the assets in a manner that acheives self-sustainable operations at the same time delivering optimal shareholder value.

Toward that end, PAOG has entered into three strategic partnerships.

PAOG recently announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough, Massachusetts. PAOG has engaged Veristat to assist in advancing PAOG with its proprietary Cannabidiol (CBD) extract for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) toward initiating an Investigational New Drug application (IND) with the Food and Drug Administration (FDA).

Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program.

Learn more about Veristat at www.veristat.com.

PAOG management anticipates a pharmaceutical development process to be a long-term endeavor. Management is committed to pursuing complimentary initiatives that have the potential to deliver revenue and profit in a shorter time frame.

PAOG has also recently engaged with the Puerto Rico Consortium for Clinical Investigation to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).

The Puerto Rico Consortium for Clinical Investigation (PRCCI) is a not-for-profit network of top performing, high-quality research sites invested in increasing the speed and quality of clinical trials. PRCCI enhances clinical research speed and quality by driving performance and efficiencies in research sites, leveraging strategic partnerships and by establishing world-class capabilities.

PAOG is targeting revenue in 2021 resulting from its nutraceutical developments.

Learn more about PRCCI at www.prcci.org.

PAOG has also entered into a strategic partnership with PURA in conjunction with PURA’s overall initiative in Farmersville, Texas. In Farmersville, PAOG plans to build a pharmaceutical grade hemp cultivation facility and hemp extract facility. The PURA partnership includes the opportunity to work in conjunction with PURA’s partnership with Alkame Holdings, Inc. (OTC Pink: ALKM). PAOG plans to work with PURA and ALKM’s co-packing operations in the delivery of its CBD nutraceutical care solutions for those experiencing issues associated with COPD.

In a closing note to the strategic outlook, PAOG management is pleased to announce it has made the necessary application to authorize the issuance of a dividend of one share of PAOG stock to every holder of one share of PURA stock in accordance with the terms of the acquisition of the hemp cultivation business from PURA last year. PAOG anticipates announced dividend dates soon.

Learn more about PAOG at www.paogroupinc.com.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION

Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72072

The Artist Tree Marijuana Dispensary and Delivery in West Hollywood Hosts New Art Exhibit

0

The Artist Tree Marijuana Dispensary and Delivery in West Hollywood hosts Roger James, a self-taught Los Angeles artist and visual philosopher specializing in abstract expressionist contemporary art for it’s January art exhibition

West Hollywood, California–(Newsfile Corp. – January 14, 2021) –  The Artist Tree is a one-of-a-kind destination for art and cannabis exploration with locations across Southern California. As one of the only art exhibition spaces currently open, the West Hollywood location provides a unique venue for artists to display their works and to comment on current events. Starting January 13th, The Artist Tree Marijuana Dispensary location in West Hollywood will be exhibiting art by Los Angeles artist, Roger James (b.1965). James’ artwork is influenced by his work in the fashion industry and he primarily works on canvas. The painter’s work reveals flexibility in thoughts, chaotic forms, vigorous hues and intentional toughness. He sees the beauty in an imperfect psychedelic world. James quoted “the amalgam of several colors is like notes in classical music. There is deep meaning but that depends on your personal interpretation.”

The Artist Tree was created by Lauren Fontein, Aviv Halimi, and brothers Avi Kahan and Mitchell Kahan. The team built The Artist Tree to celebrate art and community, while providing a welcoming place for people to enjoy cannabis. The Artist Tree team also owns additional dispensaries in Riverside, Corona, El Sobrante, and Los Angeles, which are scheduled to open in the next 12 months.

“The Artist Tree will enhance your perception of the arts and change how you experience cannabis,” says Fontein. “Constantly changing art displays and the best cannabis products available are integrated with interactive educational hubs throughout the space. Shopping with us is an immersive experience unlike any cannabis retail location in California.”

The Artist Tree Marijuana Dispensary and Delivery Hollywood location houses a dispensary and delivery service, a rotating gallery of local art, and a cannabis learning center. The most striking education hub is the beautifully designed Cultivation Learning Center, a 10 x 15 enclosed glass room containing live cannabis clone plants. Guests are encouraged to walk through the glass cube and visualize the entire craft cannabis production process with cloned plants, led by The Artist Tree’s cultivation guides.

The flagship retail store offers a variety of cannabis products – vape cartridges and topicals, edibles, CBD wellness products, craft strains, premium concentrates and pre-rolls. Featured brand products are showcased in secured custom display tables designed to allow The Artist Tree’s certified Guides to assist customers with walkthrough consultations and product interaction. Interactive touch pads for ordering products are positioned throughout the retail showroom with built in product and brand information. A secondary sales area and lounge is available for private consultations and personalized concierge experiences for individual guests or small groups.

Converting the retail space formerly occupied by Frontrunners shoe store, The Artist Tree has created a museum-esque environment with a seamless floorplan, industrial detailing, eco friendly concrete, split face basalt, and inlaid glass sections throughout the interior. The space was designed by LEED certified architectural firm, Retail Design Collaborative.

The Artist Tree is the only business applicant to qualify for West Hollywood’s cannabis licenses in all five categories, which include recreational cannabis sales, medical cannabis sales, cannabis delivery, operation of a cannabis lounge offering edible products, and operation of a lounge where cannabis smoking and vaping is permitted and edible products can be consumed.

The Artist Tree in West Hollywood retail and art space is open daily from 8:00 AM – 9:50 PM at 8625 Santa Monica Blvd, West Hollywood, CA 90069. The Artist Tree offer delivery and express pick up, accepting online orders at The Artist Tree Marijuana Dispensary and Delivery Hollywood. Details on The Artist Tree’s upcoming consumption lounges will be announced soon.

Press Contact:
Lauren Fontein
lauren@theartisttree.com
(213) 700-6858

# # #

About The Artist Tree

The Artist Tree was founded by Lauren Fontein, Aviv Halimi, Avi Kahan and Mitchell Kahan. With more than 13 years of experience in the California cannabis industry, The Artist Tree team is the only business applicant to qualify for West Hollywood’s cannabis licenses in all five categories, which include recreational cannabis sales, medical cannabis sales, cannabis delivery, operation of a cannabis lounge offering edible products and operation of a lounge where cannabis smoking and vaping is permitted and edible products can be consumed. The Artist Tree’s mission is to provide safe access to legal cannabis, raise awareness of the health benefits of cannabis, showcase artists from the community and break stereotypes surrounding cannabis sales and consumption. For driving directions, click here: https://g.page/marijuanadispensaryhollywood.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/71987

Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.

0

Genetic Screening Test Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols

Vancouver, British Columbia–(Newsfile Corp. – January 14, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company“) is pleased to announce that the Company completed its acquisition of HaluGen Life Sciences Inc. (“HaluGen“), a biotech company in the business of developing and commercializing a pre-screening test to identify genetic markers predictive of an individual’s reaction to hallucinogenic drugs. The Company acquired 100% of the issued and outstanding common shares in the capital of HaluGen (the “HaluGen Shares“) from the shareholders of HaluGen (the “HaluGen Shareholders“) pursuant to a share exchange agreement among the Company, HaluGen and the HaluGen Shareholders, resulting in HaluGen becoming a wholly-owned subsidiary of Entheon (the “Acquisition“).

“This acquisition supports Entheon’s innovative data-driven approach to developing psychedelic-assisted psychotherapeutic (PAP) protocols to treat substance use disorders and provides an opportunity to strengthen category leadership in psychedelic therapy and drug discovery,” said Chief Executive Officer of Entheon, Timothy Ko. “Importantly, it will improve our tools to screen patients for underlying psychiatric disorders prior to undertaking PAP, and gather data linking genetics to outcomes. By adding this layer of personalized medicine and data, we seek to add an additional measure of safety and predictability to PAP, and to aggregate data that can be used to infer appropriateness of specific molecules in PAP.”

The Acquisition

In consideration for the HaluGen Shares, the Company issued an aggregate of 5,100,000 common shares (the “Consideration Shares“) to the HaluGen Shareholders.

The Consideration Shares are subject to contractual restrictions on transfer and will be released in accordance with the following schedule:

(a) 1,275,000 Consideration Shares on the closing of the Acquisition (the “Closing Date“);

(b) 1,275,000 Consideration Shares on the date that is four (4) months following the Closing Date;

(c) 1,275,000 Consideration Shares on the date that is eight (8) months following the Closing Date; and

(d) 1,275,000 Consideration Shares on the date that is 12 months following the Closing Date.

In addition to the Consideration Shares, the Company may issue up to an additional 900,000 common shares (the “Compensation Shares“) to Lobo Genetics Inc. (“Lobo“), in connection with a product development agreement dated November 13, 2020, as amended on January 14, 2021 (the “Product Development Agreement“), among the Company, HaluGen and Lobo. The issuance of the Compensation Shares is subject to Lobo fulfilling certain performance milestones in accordance with the terms of the Product Development Agreement.

All securities issued or issuable in connection with the Product Development Agreement are subject to a statutory hold period expiring four months and a day from the date of issue.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products“) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

About HaluGen Life Sciences Inc.

HaluGen is developing a DNA testing and personalized psychedelic pre-screening platform that provides genetic, personal and familial insights to better inform the psychedelic experience, with the goal of improving patient care and reducing side effects and risk. HaluGen’s genetic-based psychedelic pre-screening platform will help evaluate an individual’s overall sensitivity and risk profile when using hallucinogenic drugs. This platform will be the first of its kind and is expected to produce test results within days.

On Behalf of the Board of Directors,

Timothy Ko, CEO

For more information, please contact the Company at:

Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Telephone: +1 (778) 919-8615
joe@entheonbiomedical.com
https://entheonbiomedical.com/

For media inquiries, please contact Crystal Quast at:

Bullseye Corporate
Crystal Quast
Telephone: +1 (647) 529-6364
quast@BullseyeCorporate.com

Cautionary Note on Forward Looking Information

This news release includes certain forward-looking statements and forward-looking information (collectively, “forward-looking statements“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein including, without limitation, statements with respect to the issuance of the Compensation Shares, generation of revenue by the Company and the anticipated business plans and timing of future activities of the Company, are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Often, but not always, forward looking information can be identified by words such as “pro forma”, “plans”, “expects”, “will”, “may”, “should”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and other factors include, among others, the Company being able to follow through with anticipated business plans and timing of future activities of the Company, completion of the milestones in connection with the issuance of the Compensation Shares, the ability of the Company to obtain sufficient financing to fund its business activities and plans, delays in obtaining regulatory approvals (including of the Canadian Securities Exchange), changes in laws, regulations and policies affecting the Company’s operations and the Company’s limited operating history.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this presentation or incorporated by reference herein, except as otherwise required by law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72060

Plant&Co. Reports on Holy Crap Breakfast Cereal Record Sales

0

~ Holy Crap Breakfast Cereals have great year in 2020 despite the economic impact of the COVID-19 pandemic ~

Toronto, Ontario–(Newsfile Corp. – January 14, 2021) – Plant&Co. Ltd. (CSE: VEGN) (FSE: VGP) (OTC PINK: VGANF) (“Plant&Co.” or the “Company“), a vertically integrated enterprise focused on the health and wellness sector, is pleased to report on the operations for its M&A target Holy Crap Brands Inc. (“Holy Crap“), further to the recent announcements (November 26, 2020 and January 7, 2021) regarding the definitive amalgamation agreement, whereby a wholly-owned subsidiary of the Company (Subco) will amalgamate with Holy Crap, to form a new division focused on creating innovative brands and products, inspired to improve lives through high-quality plant-based ingredients focused on gut-health wellness.

Since acquiring the line of healthy breakfast cereals in 2019, Holy Crap hired Ms. Donna Reddy as President with the mandate to lead the next phase of the company’s growth. Ms. Reddy, a strategic and results-driven leader in the marketing and branding industry, has revitalized the Holy Crap breakfast cereal brand by expanding the distribution channels and driving growth through the launch of new packaging and a new marketing strategy implemented to reach a broader audience and increase sales. Total number of cereal bags sold and revenue generated in 2020 versus 2019 since Ms. Reddy’s appointment increased over 129% and 166% respectively.

As reported earlier total online sales of Holy Crap’s amazing breakfast cereals were up almost 60% for the second and third quarter 2020 compared to the same time period year prior. In the second half of 2020 Holy Crap experienced a 95% increase in first time buyers online. Customer reviews talk about how great the cereal tastes and how it helps contribute to a happy gut and happy mind, making it very attractive to those health minded individuals seeking plant-based, organic, nutrient-packed healthy foods.

“As we move to the final stage of the amalgamation with Holy Crap, we wanted to congratulate Donna and her team at Holy Crap for their success throughout 2020,” said Shawn Moniz, CEO of Plant&Co. “Even COVID-19 couldn’t slow the business down with sales increasing year-over-over. With the new packaging and marketing strategy we expect to continue the growth trajectory of the breakfast cereal.”

Holy Crap breakfast cereal is a high-quality product that tastes greats, helps maintain a healthy gut, and makes consumers feel good inside and out. Emerging research has connected a healthy gut with a healthy mind, and Holy Crap customers’ reviews continue to confirm that its breakfast cereals contribute to a healthful digestive tract. With many people experiencing digestive sensitivities, Holy Crap has developed the right formulation to get people moving.

Today, Holy Crap offers four distinct SKUs all of which contain certified organic, non-gmo, kosher and gluten free ingredients, such as hemp seed, buckwheat, chia seeds, and gluten-free oats. The tasty, nutrient-packed breakfast cereals have high levels of essential amino and fatty acids, a kick of fiber, and are free from the top 9 allergens and free from any additives like added flavors, preservatives, chemicals, color, salt, or oils.

Holy Crap has built a successful distribution model with access to wholesale suppliers and close relationships with BUYBC and other BC enterprises. Today Holy Crap products are available for sale in many well-known Canadian retailers such as Save-On-Foods, London Drugs, Whole Foods (West), Georgia Main, Natures Fare, Choices Market, Nature’s Emporium, Organic Garage, Big Carrot, Ambrosia and more stores to come! The Company also has a loyal following in numerous west coast independent grocers and generates sales throughout North America online though its website www.holycrap.com and www.amazon.ca.

About Holy Crap Brands Inc.

At Holy Crap Brands Inc. our mission is to create products that inspire through innovative branding and improve lives through simple, quality ingredients that ultimately feed the connection between gut and mind. The company’s signature brand – Holy Crap – is an organic breakfast cereal for today’s consumer that expects their food to work hard for them. Our great tasting cereal helps maintain a healthy gut which creates a happy mind. For additional investor and product information please visit: www.holycrap.com.

About Plant&Co. Brands Ltd.

Plant&Co. Brands Ltd. (CSE: VEGN) (FSE: VGP) (OTC PINK: VGANF) is modern health and wellness company curating delicious plant-based foods.

For additional information, please contact: ir@plantandco.com.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the closing of the Transaction and the business plans and prospects of Holy Crap and the Company. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72048

PeakBirch Logic Expands CBD Sales into B2B with Collaborative Agreement with Namaste Technologies

0

Vancouver, British Columbia–(Newsfile Corp. – January 14, 2021) – PeakBirch Logic Inc. (CSE: PKB) (FSE: KYH2) (OTC PINK: KTNNF) (“PeakBirch” or the “Company”) is pleased to announce that it has entered a collaborative agreement with Namaste Technologies Inc. (“Namaste”) which will enable PeakBirch to sell hemp derived CBD through CannMart.com, subject to Namaste receiving approval of the TSX Venture Exchange. 

By partnering with Namaste, PeakBirch will gain a new revenue stream to include online B2B sales. PeakBirch is actively looking to expand sales to include other online B2B stores in both Canada and the United States. PeakBirch will be drop-shipping CBD and hemp-derived products for Namaste through its CannMart.com marketplace.

On December 20th, 2018 the U.S. passed the farm bill into law which included special provisions to legalize the cultivation, distribution and sale of Hemp derived products such as CBD. Since then the FDA has approved CBD products for various specific medical treatments. The market has seen exponential growth over the last two years, with growth from USD$620 million in sales in 2018 to USD$4.7 billion in sales in 2020, as reported by Brightfield Group.

“We see a lot of revenue potential in the CBD market and we are excited to be entering into a collaborative agreement with Namaste that will provide us with access to a whole new revenue stream but most importantly it marks a key milestone in our company’s growth journey. PeakBirch has been working hard behind the scenes to develop key technologies that will enable it now and in the future to scale its B2B sales,” says Marc Mulvaney, CEO of PeakBirch. “By leveraging our existing brand relationships and purchasing power we are well positioned to compete in the B2B space.”

“We first announced our 24 month collaboration arrangement with PeakBirch in September, 2020 including the possible development of business in the USA and we are delighted to see the first fruits of that collaboration today,” said Meni Morim, CEO of Namaste. “With the changing regulatory landscape improving in the USA and now this proposed entry into the U.S. hemp derived CBD market, we continue the execution of our strategy to position Namaste as a leading global cannabis company and look forward to building on this positive momentum. This development also further validates our investment in technology, as the proposed expansion will be facilitated via our marketplace technology and we are looking forward to launching more vendors onto the platform.”

To learn more about PeakBirch’s new collaborative agreement with Namaste, please contact PeakBirch using the information below.

CONTACT

Marc Mulvaney, CEO
Phone: (725) 218-3097
Email: investors@peakbirch.com

About PeakBirch

PeakBirch is a multi-brand management company providing services & related products to the cannabis industry that believes its strong focus on and investment in marketing, brand, education to help customers make sound purchasing decision, strategic brand partnerships, and a delivery software technology will create a business with the potential to generate a significant and sustained return on invested capital over the long-term.

About Namaste Technologies Inc.

Headquartered in Toronto, Canada, Namaste Technologies is a leading online platform for cannabis products, accessories, and responsible education. The Company’s ‘everything cannabis store’, CannMart.com, provides medical customers with a diverse selection of hand-picked products from a multitude of federally-licensed cultivators, all on one convenient site. The Company also distributes licensed and in-house branded cannabis and cannabis derived products to recreational consumers in Canada through a number of provincial government control boards and retailing bodies and facilitates licensed cannabis retailer sales online in Saskatchewan. Namaste’s global technology and continuous innovation address local needs in a burgeoning cannabis industry requiring smart solutions.

Information on the Company and its many products can be accessed through the links below:

NamasteTechnologies.com

NamasteMD.com

Cannmart.com

Neither the Canadian Securities Exchange nor its regulations services provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

FORWARD LOOKING INFORMATION

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include the cost of goods to be sold under the Company’s drop-shipping model, changes in government regulations or enforcement, the ability for the Company to expand its US operations or expand to international markets, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s listing statement under the Company’s profile on www.sedar.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72052